Literature DB >> 33392794

Should We Target Global Risk or Risk Factors?

Lale Tokgozoglu1, Duygu Kocyigit2.   

Abstract

PURPOSE OF REVIEW: Recent evidence has shaped the new guidelines for the management of dyslipidemia. The importance of accurate risk estimation, subclinical disease detection, and contemporary dyslipidemia management approaches are discussed in this review. RECENT
FINDINGS: Risk prediction helps determine the intensity of management strategies and identify high-risk patients. To overcome the pitfalls of the current risk prediction systems, incorporating genetic scores, biomarkers, and imaging is being explored. Key initiating event in atherogenesis is low-density lipoprotein cholesterol (LDL-C) retention in the arterial wall. Recent dyslipidemia guidelines agree that LDL-C is the primary target, but management approaches vary. Guidelines are shaped by new studies that show the benefits of high-intensity lipid lowering, especially for patients at very high-risk. Global risk assessment should be performed in all individuals for cardiovascular disease prevention. Main target should be the causal risk factors, particularly LDL-C which is one of the most important modifiable causal factors. Lower LDL-C goals will help prevent further events in very high-risk patients.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease; Dyslipidemia; Low-density lipoprotein cholesterol; Prevention; Risk estimation; Risk factor

Mesh:

Substances:

Year:  2021        PMID: 33392794     DOI: 10.1007/s11883-020-00898-w

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  4 in total

1.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

2.  High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population.

Authors:  Dimitrios Farmakis; Christian Mueller; Fred S Apple
Journal:  Eur Heart J       Date:  2020-11-01       Impact factor: 29.983

3.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

4.  Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.

Authors:  Nicholas A Marston; Marc P Bonaca; Petr Jarolim; Erica L Goodrich; Deepak L Bhatt; Philippe G Steg; Marc Cohen; Robert F Storey; Per Johanson; Stephen D Wiviott; Eugene Braunwald; Marc S Sabatine; David A Morrow
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.